CN106361703A - Finasteride nano-liposome, gel and preparation method thereof - Google Patents
Finasteride nano-liposome, gel and preparation method thereof Download PDFInfo
- Publication number
- CN106361703A CN106361703A CN201610965146.9A CN201610965146A CN106361703A CN 106361703 A CN106361703 A CN 106361703A CN 201610965146 A CN201610965146 A CN 201610965146A CN 106361703 A CN106361703 A CN 106361703A
- Authority
- CN
- China
- Prior art keywords
- finasteride
- phospholipid
- nanometer liposome
- weight
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Abstract
The invention relates to a finasteride nano-liposome and a preparation method thereof. The finasteride nano-liposome comprises finasteride, phospholipids, a flexible material and a PBS solution, wherein the weight percentage of the finasteride accounting for the phospholipids is 2.5% to 10%, the weight percentage of the flexible material accounting for the phospholipids is 20% to 50%, and the weight percentage of the PBS solution accounting for the phospholipids is 2.5% to 10%. According to the finasteride nano-liposome, the disadvantage, such as poor percutaneous permeability, of the finasteride is improved, the phospholipids and the flexible material are taken as a carrier system, and the prepared finasteride nano-liposome is simple to operate and good in repeatability and prevents from using an organic solvent with large toxicity, drugs are delivered to skin deep layers by using high deformability and efficient permeability of the flexible nano-liposome, and a better therapeutic effect is exerted.
Description
Technical field
The present invention relates to pharmaceutical technology field, more particularly to a kind of finasteride nanometer liposome, gel and its preparation
Method.
Background technology
Androgenic alopecia (aga) is topmost type in pathologic alopecia, and its pathological manifestations is progressive hair
Sparse, with hair follicle atrophy, patient's head and frontal temporal part are mainly involved in alopecia distribution.Epidemiological study shows, China man
More than 20%, prevalence grows steadily the total incidence of property androgenic alopecia with age, and this disease can cause patient
The psychological burden of (especially young patient) and stress, impact patient social behavior enthusiasm.Androgenic alopecia and trouble
In person's body, the amount of androgen is relevant, and alopecia mechanism is: testosterone is converted into dihydrotestosterone, receptor affinity by 5α-reductase
With biological activity be higher than testosterone, the biotic factor causing alopecia can be produced with specific receptor after being combined, therefore pass through suppression 5 α-
Reductase activity can effectively prevent and treat androgenic alopecia.
Finasteride is a kind of 4- aza sterides hormone medicine, is the specific inhibitor of type 5α-reductase, can be competing
Striving property suppressive 5α-reductase activity, thus suppress testosterone in the patient to the conversion of dihydrotestosterone, to reduce dihydrotestosterone
Level.Finasteride is developed by merk company of the U.S., and China ratified this medicine import in 1994, main dosage form have tablet and
Capsule, is one of the key agents being clinically used for treating androgenic alopecia at present, typically continuously medication more than 3 months or more
Competence exertion curative effect long, 3927 male patients grind to finasteride oral tablets treatment androgenic alopecia safety evaluatio
In studying carefully, have 1.7% in 945 patients of medication therapy groups because of untoward reaction stopped treatment, hyposexuality in 1.8% patient,
After the listing of finasteride tablet, the adverse events of report have: anaphylaxiss (erythra, prurituss, urticaria and lip swelling), breast
Tenderness, testicular pain, ejaculation are abnormal.
Type 5α-reductase in human body is distributed mainly on prostate, seminal vesicle, hair follicle and perifollicolar tissue, therefore, can
Consider for finasteride to make percutaneous drug administration preparation, be applied directly to affected part, to reduce the haemoconcentration of medicine, increase skin office
Portion's drug level, thus reduce the side effect that patient's Long-term Oral finasteride brings.Because finasteride is practically insoluble in water,
There is strong lipotropy, make external preparation and be easily detained in keratodermatitis, lead to skin deep part drug level difficult to reach onset
Concentration, conventional chemical/physical promotees to ooze means, can change skin texture or cause the irreversible damage of skin, and life-time service will
Destroy patient skin tissue.
Accordingly, it would be desirable to develop a kind of new dosage form to improve the defect of finasteride percutaneous permeability difference.
Content of the invention
Based on this, it is an object of the invention to provide a kind of excellent finasteride nanometer liposome of percutaneous permeability.
Specific technical scheme is as follows:
A kind of finasteride nanometer liposome, including finasteride, phospholipid, flexible material and pbs solution；That hero wherein non-
Amine accounts for the 2.5-10% of the percentage by weight of phospholipid, and flexible material accounts for the 20-50% of the percentage by weight of phospholipid, and pbs solution accounts for
The 2.5-10% of the percentage by weight of phospholipid.
Wherein in some embodiments, described phospholipid be selected from Egg Yolk Lecithin (PC-98T), soybean lecithin, hydrogenated soy phosphatidyl choline,
Cephalin, DPPC, DSPC, tin dilaurate phosphatidylcholine or two Semen Myristicae phospholipid
One or more of phatidylcholine.
Wherein in some embodiments, described phospholipid is selected from soybean lecithin.
Wherein in some embodiments, described flexible material is selected from cholesterol and/or film softening agent.
Wherein in some embodiments, described film softening agent is selected from Tween 80, sorbester p17, sodium cholate or sodium deoxycholate
One or more.
It is a further object of the present invention to provide the preparation method of above-mentioned finasteride nanometer liposome.
Specific technical scheme is as follows:
The preparation method of finasteride nanometer liposome, comprises the steps:
(1) phospholipid, cholesterol, finasteride are dissolved in organic solvent, in 20-50 DEG C, 0.06-0.09mpa, 20-
Under the conditions of 100rpm, rotary evaporation removes organic solvent；
Finasteride accounts for the 2.5-10% of the percentage by weight of phospholipid；
(2) add the pbs solution being dissolved with film softening agent, under 30-60 DEG C of water-bath, normal pressure rotates 15-90min, obtains non-
The colostric fluid of that male amine nanometer liposome；
The weight summation of cholesterol and film softening agent accounts for the 20-50% of the percentage by weight of phospholipid；Pbs solution accounts for phospholipid
The 2.5-10% of percentage by weight；
(3) described colostric fluid is carried out Probe Ultrasonic Searching 2-5min, 2000-6000rpm is centrifuged, obtain final product described after microporous filter
Finasteride nanometer liposome.
Wherein in some embodiments, described phospholipid be selected from Egg Yolk Lecithin (PC-98T), soybean lecithin, hydrogenated soy phosphatidyl choline,
Cephalin, DPPC, DSPC, tin dilaurate phosphatidylcholine or two Semen Myristicae phospholipid
One or more of phatidylcholine；Described film softening agent is selected from one of Tween 80, sorbester p17, sodium cholate or sodium deoxycholate
Or it is several；Described organic solvent is dehydrated alcohol.
It is a further object of the present invention to provide a kind of preparation method of finasteride nanometer liposome gel.
The preparation method of finasteride nanometer liposome gel, comprises the steps:
Claim 6-7 any one preparation method is prepared finasteride nanometer liposome and is added to gel-type vehicle
In, stir, obtain final product described finasteride nanometer liposome gel.
Wherein in some embodiments, described gel-type vehicle prepares by the following method: with 8-12 weight portion Carbomer
For substrate, 45-55 parts by weight of glycerin is wetting agent, and 0.5-1.5 parts by weight sodium is preservative, 12-15 weight portion three second
Hydramine is ph regulator, adds 14-21 weight portion water, and stirring obtains final product.
It is a further object of the present invention to provide a kind of finasteride nanometer liposome gel.
The finasteride nanometer liposome gel that above-mentioned preparation method prepares.
Above-mentioned finasteride flexible nano-liposomes and its gel, improve the percutaneous permeability difference of finasteride not
Foot.Make carrier system, the flexible nano-liposomes of prepared finasteride, simple to operate, repeatability using phospholipid and flexible material
Well, avoid the organic solvent big using toxicity, by using high deformation and the high-effective penetrating of flexible nano-liposomes, will
Drug delivery, to deep skin, preferably plays curative effect.
Specific embodiment
For the ease of understanding the present invention, below the present invention is described more fully.But, the present invention can be with many
Different forms is realizing however it is not limited to embodiment described herein.On the contrary, provide the purpose of these embodiments be make right
The understanding of the disclosure is more thoroughly comprehensive.
Unless otherwise defined, all of technology used herein and scientific terminology and the technical field belonging to the present invention
The implication that technical staff is generally understood that is identical.The term being used in the description of the invention herein is intended merely to description tool
The purpose of the embodiment of body is it is not intended that in limiting the present invention.Term as used herein "and/or" includes one or more phases
The arbitrary and all of combination of the Listed Items closing.
Embodiment 1-3
A kind of finasteride nanometer liposome, comprises the following raw material (weight portion) component, is shown in Table 1:
Table 1 principal agent and flexible matrix material prescription
Preparation method is as follows:
(1) by soybean lecithin, cholesterol and finasteride by dehydrated alcohol (consumption is defined by dissolving above-mentioned raw materials)
Dissolving, is placed in eggplant type flask；
(2) eggplant type flask is placed in rotary evaporator, in 37 DEG C of waters bath with thermostatic control, decompression rotary evaporation removes anhydrous second
Alcohol, forms uniform class membrane of lipoprotein in bottle wall；
(3) prepare the pbs solution of sodium deoxycholate, this solution is added and is formed in the eggplant-shape bottle of thin film to step (2), 40
Under DEG C water-bath, normal pressure rotates, hydration time 60min, the colostric fluid of prepared finasteride nanometer liposome；
(4) colostric fluid of the finasteride nanometer liposome of step (3) is carried out Probe Ultrasonic Searching, the time is 3min, low speed
Centrifugation 5min, finally extrudes through 0.45 μm of microporous filter membrane, obtains finasteride nanometer liposome.
Embodiment 4
The physicochemical property of the finasteride nanometer liposome of above-described embodiment 1-3 preparation.
The finasteride nanometer liposome of embodiment 1-3 preparation is evaluated as follows:
(1) mean diameter and pdi:
Draw the flexible nano-liposomes suspension of appropriate finasteride with liquid-transfering gun, add to quartzy measuring cell, pure
Water is diluted to 1ml, using mean diameter and the polydispersity index (pdi) of Laser Scattering Particle instrument determination sample.
(2) mensure of envelop rate:
Using ultrafiltration centrifuging separation flexible nano-liposomes and non-encapsulated free drug, high effective liquid chromatography for measuring
Content.Precision measures in the super filter tube of flexible nano-liposomes suspension 500 μ l to 50kd of finasteride, low-speed centrifugal
15min, takes the flexible nano-liposomes of the finasteride being trapped, and adds methanol constant volume 5ml, ultrasonic emulsion breaking, 0.22 μm of micropore
Membrane filtration, sample introduction is analyzed, and obtains the dose of encapsulating in flexible nano-liposomes.
Take the flexible nano-liposomes suspension 500 μ l of finasteride, be directly added into methanol constant volume 5ml, ultrasonic emulsion breaking,
0.22 μm of filtering with microporous membrane, sample introduction is analyzed, and obtains total dose.
Envelop rate=(dose of encapsulating/total dose) × 100%
Result is as shown in table 2:
Table 2 physicochemical property table
Embodiment 5
The Ligustrazine hydrochloride Journal of Sex Research of finasteride nanometer liposome gel:
The finasteride nanometer liposome of embodiment 1 is made gel, preparation method is as follows:
The preparation of gel-type vehicle: with 10 weight portion Carbomer as substrate, 50 parts by weight of glycerin are wetting agent, 1 weight portion benzene
Sodium formate is preservative, and 13.5 weight portion triethanolamine are ph regulator, adds 17.5 weight portion water, and stirring obtains final product gel base
Matter；
To in above-mentioned gel-type vehicle, add embodiment 1 to prepare finasteride nanometer liposome, add suitable quantity of water, stir
Mix uniformly, obtain final product finasteride nanometer liposome gel (sample a).
Prepare finasteride flexible nano-liposomes gel (sample a), finasteride conventional liposome gel (sample respectively
B, in this sample formulations do not contain the present invention flexible material) with finasteride ordinary gel (sample c, this sample directly by non-that
Male amine is scattered in gel-type vehicle), every g gel is about 0.25mg containing finasteride.Take in the breast of percutaneous permeation experiment
Pig abdominal part Corii Sus domestica, is tested using modified form franz diffusion cell, by Corii Sus domestica horny layer upward, is installed on diffusion cell, respectively
Smear 0.2g；Reception liquid is 20%peg400- normal saline, 32 ± 1 DEG C of experimental temperature, mixing speed 200rpm, in regulation
Between point take out reception liquid, and supplement same volume fresh reception liquid, after last time point takes reception liquid, calculate 24h medicine
Accumulative skin permeation amount (q24), except the gel on destratum corneum wiped clean, horny layer is separated with epidermis dermis layer, respectively
Shred to rotten shape, with the content of finasteride in methanol extraction, and Detection and Extraction liquid, respectively horny layer hold-up (qsc) and table
Skin skin corium hold-up (qep).Result is as shown in table 3:
Table 3 Ligustrazine hydrochloride result table
Result shows, finasteride nanometer liposome has good transdermal performance really, and is remarkably improved activity
Composition is in the hold-up of epiderm skin skin corium.
Meaning of the present invention is for finasteride to be prepared into flexible nano-liposomes gel, for topical administration, promotes
Finasteride penetrates into deep skin, is that fat-soluble medicine external preparation provides thinking and method reference, has and send out greatly very much
Exhibition prospect.
Each technical characteristic of embodiment described above can arbitrarily be combined, for making description succinct, not to above-mentioned reality
The all possible combination of each technical characteristic applied in example is all described, as long as however, the combination of these technical characteristics is not deposited
In contradiction, all it is considered to be the scope of this specification record.
Embodiment described above only have expressed the several embodiments of the present invention, and its description is more concrete and detailed, but simultaneously
Can not therefore be construed as limiting the scope of the patent.It should be pointed out that coming for those of ordinary skill in the art
Say, without departing from the inventive concept of the premise, some deformation can also be made and improve, these broadly fall into the protection of the present invention
Scope.Therefore, the protection domain of patent of the present invention should be defined by claims.
Claims (10)
1. a kind of finasteride nanometer liposome is it is characterised in that include finasteride, phospholipid, flexible material and pbs solution；
Wherein finasteride accounts for the 2.5-10% of the percentage by weight of phospholipid, and flexible material accounts for the 20-50% of the percentage by weight of phospholipid,
Pbs solution accounts for the 2.5-10% of the percentage by weight of phospholipid.
2. finasteride nanometer liposome according to claim 1 is it is characterised in that described phospholipid is selected from egg yolk lecithin
Fat, soybean lecithin, hydrogenated soy phosphatidyl choline, cephalin, DPPC, DSPC, two
One or more of lauric acid phosphatidylcholine or two Semen Myristicae phosphatidylcholines.
3. finasteride nanometer liposome according to claim 1 is it is characterised in that described phospholipid is selected from Semen sojae atricolor lecithin
Fat.
4. the finasteride nanometer liposome according to any one of claim 1-3 is it is characterised in that described flexible material selects
From cholesterol and/or film softening agent.
5. finasteride nanometer liposome according to claim 4 is it is characterised in that described film softening agent is selected from tween
80th, one or more of sorbester p17, sodium cholate or sodium deoxycholate.
6. the preparation method of finasteride nanometer liposome is it is characterised in that comprise the steps:
(1) phospholipid, cholesterol, finasteride are dissolved in organic solvent, in 20-50 DEG C, 0.06-0.09mpa, 20-
Under the conditions of 100rpm, rotary evaporation removes organic solvent；
Finasteride accounts for the 2.5-10% of the percentage by weight of phospholipid；
(2) add the pbs solution being dissolved with film softening agent, under 30-60 DEG C of water-bath, normal pressure rotates 15-90min, and get Fei Na is male
The colostric fluid of amine nanometer liposome；
The weight summation of cholesterol and film softening agent accounts for the 20-50% of the percentage by weight of phospholipid；Pbs solution accounts for the weight of phospholipid
The 2.5-10% of percentage ratio；
(3) described colostric fluid is carried out Probe Ultrasonic Searching 2-5min, 2000-6000rpm is centrifuged, obtain final product after microporous filter described non-that
Male amine nanometer liposome.
7. preparation method according to claim 6 is it is characterised in that described phospholipid is selected from Egg Yolk Lecithin (PC-98T), Semen sojae atricolor lecithin
Fat, hydrogenated soy phosphatidyl choline, cephalin, DPPC, DSPC, tin dilaurate phosphatidyl
One or more of choline or two Semen Myristicae phosphatidylcholines；Described film softening agent be selected from Tween 80, sorbester p17, sodium cholate or
One or more of sodium deoxycholate；Described organic solvent is dehydrated alcohol.
8. the preparation method of finasteride nanometer liposome gel is it is characterised in that comprise the steps:
Claim 6-7 any one preparation method is prepared finasteride nanometer liposome be added in gel-type vehicle, stir
Mix uniformly, obtain final product described finasteride nanometer liposome gel.
9. preparation method according to claim 8 is it is characterised in that described gel-type vehicle prepares by the following method:
With 8-12 weight portion Carbomer as substrate, 45-55 parts by weight of glycerin is wetting agent, and 0.5-1.5 parts by weight sodium is anti-corrosion
Agent, 12-15 weight portion triethanolamine is ph regulator, adds 14-21 weight portion water, and stirring obtains final product.
10. the finasteride nanometer liposome gel that any one of claim 8-9 preparation method prepares.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610965146.9A CN106361703A (en) | 2016-10-31 | 2016-10-31 | Finasteride nano-liposome, gel and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610965146.9A CN106361703A (en) | 2016-10-31 | 2016-10-31 | Finasteride nano-liposome, gel and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106361703A true CN106361703A (en) | 2017-02-01 |
Family
ID=57894158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610965146.9A Pending CN106361703A (en) | 2016-10-31 | 2016-10-31 | Finasteride nano-liposome, gel and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106361703A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019084503A1 (en) * | 2017-10-27 | 2019-05-02 | Victor Hasson | Topical formulations for treating dermatological disorders including male pattern baldness |
| CN110448525A (en) * | 2018-05-08 | 2019-11-15 | 无锡派列博生物医药科技有限公司 | A kind of external application Finasteride lipid nanometer preparation and preparation method thereof prevented hair loss with growth-promoting hair |
| CN111163759A (en) * | 2018-06-18 | 2020-05-15 | 无尽医疗有限公司 | Naniposome-microbubble assemblies encapsulating hair loss treatment drugs and compositions comprising the same for reducing or treating hair loss |
| CN111329832A (en) * | 2020-02-08 | 2020-06-26 | 中山大学 | Nanometer lipid carrier microneedle for treating alopecia and application thereof |
| CN113350288A (en) * | 2021-06-09 | 2021-09-07 | 山东良福制药有限公司 | All-trans-retinoic acid/betamethasone co-loaded flexible nano-liposome and preparation method of gel thereof |
| CN113425845A (en) * | 2021-08-10 | 2021-09-24 | 成都倍特药业股份有限公司 | Carrier preparation for preventing and/or treating alopecia and preparation method and application thereof |
| CN115400085A (en) * | 2022-09-02 | 2022-11-29 | 南昌大学 | Finasteride lipid vesicles and preparation method and application thereof |
| CN115501181A (en) * | 2021-06-07 | 2022-12-23 | 武汉科福新药有限责任公司 | Nadolol flexible nano gel emulsion and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1555804A (en) * | 2004-01-06 | 2004-12-22 | 浙江大学 | Phenasteroid gel preparation |
-
2016
- 2016-10-31 CN CN201610965146.9A patent/CN106361703A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1555804A (en) * | 2004-01-06 | 2004-12-22 | 浙江大学 | Phenasteroid gel preparation |
Non-Patent Citations (3)
| Title |
|---|
| MAJID TABBAKHIAN,ET AL: "Enhancement of follicular delivery of finasteride by liposomes and niosomes 1.In vitro permeation and in vivo deposition studies using hamster flank and ear models", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》 * |
| 彭司勋主编: "《中国药学年鉴·2012》", 31 January 2013, 第二军医大学出版社 * |
| 饶跃峰等: "非那甾胺醇质体和脂质体的经皮渗透比较研究", 《中国药学杂志》 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11786466B2 (en) | 2017-10-27 | 2023-10-17 | XYON Health Inc. | Topical formulations for treating dermatological disorders including male pattern baldness |
| WO2019084503A1 (en) * | 2017-10-27 | 2019-05-02 | Victor Hasson | Topical formulations for treating dermatological disorders including male pattern baldness |
| EP3977983A1 (en) * | 2017-10-27 | 2022-04-06 | XYON Health Inc. | Topical formulations for treating dermatological disorders including male pattern baldness |
| CN110448525A (en) * | 2018-05-08 | 2019-11-15 | 无锡派列博生物医药科技有限公司 | A kind of external application Finasteride lipid nanometer preparation and preparation method thereof prevented hair loss with growth-promoting hair |
| CN111163759A (en) * | 2018-06-18 | 2020-05-15 | 无尽医疗有限公司 | Naniposome-microbubble assemblies encapsulating hair loss treatment drugs and compositions comprising the same for reducing or treating hair loss |
| US11337923B2 (en) | 2018-06-18 | 2022-05-24 | Moogene Medi Co., Ltd. | Nanoliposome-microbubble conjugate including drug for hair loss treatment encapsulated in nanoliposome and composition for alleviating or treating hair loss containing same |
| US11944705B2 (en) | 2018-06-18 | 2024-04-02 | Moogene Medi Co., Ltd. | Nanoliposome-microbubble conjugate including drug for hair loss treatment encapsulated in nanoliposome and composition for alleviating or treating hair loss containing same |
| CN111329832A (en) * | 2020-02-08 | 2020-06-26 | 中山大学 | Nanometer lipid carrier microneedle for treating alopecia and application thereof |
| CN111329832B (en) * | 2020-02-08 | 2021-07-16 | 中山大学 | Nanometer lipid carrier microneedle for treating alopecia and application thereof |
| CN115501181A (en) * | 2021-06-07 | 2022-12-23 | 武汉科福新药有限责任公司 | Nadolol flexible nano gel emulsion and preparation method thereof |
| CN113350288A (en) * | 2021-06-09 | 2021-09-07 | 山东良福制药有限公司 | All-trans-retinoic acid/betamethasone co-loaded flexible nano-liposome and preparation method of gel thereof |
| CN113425845A (en) * | 2021-08-10 | 2021-09-24 | 成都倍特药业股份有限公司 | Carrier preparation for preventing and/or treating alopecia and preparation method and application thereof |
| CN115400085A (en) * | 2022-09-02 | 2022-11-29 | 南昌大学 | Finasteride lipid vesicles and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106361703A (en) | Finasteride nano-liposome, gel and preparation method thereof | |
| JPS62132819A (en) | Skin acting agent | |
| CN106420610A (en) | Ionic liquid microemulsion and application thereof | |
| CN105434337B (en) | Propranolol Hydrochloride Submicron Emulsion gel and its preparation method and application | |
| CN103239391B (en) | Tacrolimus ointment | |
| Dev et al. | Emulgels: a novel topical drug delivery system | |
| CN109069418A (en) | topical composition comprising tacrolimus | |
| CN108066279A (en) | A kind of medicinal external emulsifiable paste composition containing benzene alkene not moral | |
| CN102657602B (en) | 3,5-dyhydroxyl-4-isopropyl diphenylethene chitosan gel and preparation method thereof | |
| CN102579437B (en) | Tacrolimus composition containing alcohol and preparation method of tacrolimus composition | |
| CN109718228A (en) | The antitumor Lymph Node Metastasis of mitoxantrone acts on and its pharmaceutical preparation | |
| Zou et al. | Accelerating transdermal delivery of insulin by ginsenoside nanoparticles with unique permeability | |
| CN105125592A (en) | Medicine containing toad venom lipid-soluble substances and preparation method thereof | |
| CN106924176A (en) | A kind of TAM flexible nano-liposomes gel and preparation method thereof | |
| CN104958257B (en) | A kind of Cryptotanshinone skin keratin lipoid body preparation and preparation method thereof | |
| CN102872288B (en) | Frankincense rheumatism aerosol for curing rheumatism bone ache and preparation method thereof | |
| KR102216549B1 (en) | Ultrasound-Assisted Delivery System using Microcapsule Platform Containing Nanobubbles and Drugs | |
| CN107320699A (en) | A kind of Chinese medicine compound prescription micro emulsion gels and its production and use | |
| CN108743534B (en) | Tripterine or tripterine derivative vesicle and preparation method thereof | |
| CN108969396A (en) | A kind of gel skin care item and preparation method thereof containing NMN | |
| CN108926549A (en) | Rivastigmine gel emplastrum and preparation method thereof | |
| CN107638304A (en) | A kind of α black bearberry glycoside compositions of high Skin Cell infiltration and its preparation method and application | |
| CN101623286A (en) | Transdermal administration composite containing cucurbitacin-type active ingredient | |
| Kumar et al. | Enhanced epidermal localization of topically applied steroids using SPACE™ peptide | |
| CN108143711A (en) | A kind of medicinal external emulsifiable paste composition containing luliconazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170201 |